Brii Biosciences Limited said its BRiSC™ platform will initially direct dual-targeting applications toward prevalent metabolic dysfunctions, where complex biology or overlapping conditions may call for coordinated modulation of multiple targets.
Brii describes BRiSC™ as a discovery and development platform for small interfering RNA (siRNA) medicines. The company says it brings together chemical modification and sequence optimization with targeted delivery and designs intended to address two targets. Brii says the combined capabilities are meant to improve selectivity, performance and therapeutic reach.
The platform's dual-targeting architecture is designed to let one siRNA medicine silence two distinct targets. Brii said disease areas with complex biology or overlapping comorbidities may benefit from modulating multiple targets together. It has not identified the metabolic conditions or specific target pairs it plans to pursue.
Brii says its laboratories in Beijing and Shanghai support work spanning target discovery, translational science and preclinical development. The company said BRiSC™ is already being used in multiple internal discovery programs, but did not identify those programs or describe their development stages.
Brii Bio Chief Science Officer Dr. Brian Johns said the company aims to develop RNA treatments with broader patient benefits. “Our goal is to develop differentiated RNA therapeutics that can deliver broader and more meaningful benefits for patients,” he said. The announcement reported no experimental or clinical results and gave no timeline for the programs.
